Nomura Asset Management Co. Ltd. Grows Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Nomura Asset Management Co. Ltd. lifted its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 26.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 119,646 shares of the medical equipment provider's stock after purchasing an additional 24,842 shares during the quarter. Nomura Asset Management Co. Ltd. owned about 0.05% of Hologic worth $9,746,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of HOLX. Y Intercept Hong Kong Ltd purchased a new stake in Hologic in the third quarter valued at $1,985,000. MML Investors Services LLC lifted its holdings in shares of Hologic by 10.1% in the 3rd quarter. MML Investors Services LLC now owns 41,038 shares of the medical equipment provider's stock valued at $3,343,000 after buying an additional 3,775 shares during the period. Orion Portfolio Solutions LLC boosted its stake in shares of Hologic by 10.4% in the third quarter. Orion Portfolio Solutions LLC now owns 65,812 shares of the medical equipment provider's stock worth $5,361,000 after buying an additional 6,183 shares during the last quarter. XTX Topco Ltd acquired a new stake in Hologic during the third quarter worth about $637,000. Finally, National Bank of Canada FI raised its position in Hologic by 196.5% during the third quarter. National Bank of Canada FI now owns 190,912 shares of the medical equipment provider's stock valued at $15,551,000 after acquiring an additional 126,528 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Price Performance

Shares of Hologic stock traded down $0.44 on Thursday, hitting $75.09. 2,839,504 shares of the company were exchanged, compared to its average volume of 1,622,966. Hologic, Inc. has a 1-year low of $69.36 and a 1-year high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $17.04 billion, a price-to-earnings ratio of 22.76, a price-to-earnings-growth ratio of 2.37 and a beta of 0.96. The company has a 50-day moving average price of $79.53 and a 200 day moving average price of $78.58.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.01. The business had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company's revenue for the quarter was up 4.5% on a year-over-year basis. During the same period last year, the company earned $0.89 EPS. As a group, sell-side analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the company's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares of the company's stock, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.75% of the stock is owned by insiders.

Wall Street Analyst Weigh In

HOLX has been the topic of several recent research reports. Royal Bank of Canada upped their price objective on Hologic from $86.00 to $89.00 and gave the stock a "sector perform" rating in a research report on Tuesday, November 5th. Citigroup downgraded shares of Hologic from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. BNP Paribas upgraded shares of Hologic to a "strong-buy" rating in a research report on Tuesday. Needham & Company LLC reiterated a "buy" rating and issued a $90.00 price objective on shares of Hologic in a research report on Tuesday. Finally, Mizuho dropped their target price on Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a research report on Tuesday, November 5th. Five research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $89.50.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.